GH Research PLC (GHRS)
About GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $1.5B
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.5B
- Shares outstanding
- 53.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 25, 2021
GH Research PLC (GHRS) Stock Price
- Trading 6% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review GH Research PLC.
Write a review
News about GH Research PLC
News & sentiment via Polygon.io
GH Research PLC: frequently asked questions
Is GH Research PLC an American company?
GH Research PLC is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is GH Research PLC publicly traded?
Yes — GH Research PLC is a publicly traded company. Its stock trades under the ticker symbol GHRS on the NASDAQ.
What does GH Research PLC do?
GH Research PLC is an American Pharmaceuticals company in the Health & Beauty sector.
